October 14, 2019 October 14, 2019Categories Trial ResultsTrial Results: With E1912, there is a new standard of care for the initial treatment of patients with chronic lymphocytic leukemiaThe combination of ibrutinib plus rituximab was superior to standard treatment for CLL patients age 70 and younger.